Cargando…
Reasons for Failed Trials of Disease-Modifying Treatments for Alzheimer Disease and Their Contribution in Recent Research
Despite all scientific efforts and many protracted and expensive clinical trials, no new drug has been approved by FDA for treatment of Alzheimer disease (AD) since 2003. Indeed, more than 200 investigational programs have failed or have been abandoned in the last decade. The most probable explanati...
Autores principales: | Yiannopoulou, Konstantina G., Anastasiou, Aikaterini I., Zachariou, Venetia, Pelidou, Sygkliti-Henrietta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966425/ https://www.ncbi.nlm.nih.gov/pubmed/31835422 http://dx.doi.org/10.3390/biomedicines7040097 |
Ejemplares similares
-
Systematic review of the association between Alzheimer’s disease and chronic glaucoma
por: Tsilis, Alexandros G, et al.
Publicado: (2014) -
Donepezil Treatment for Alzheimer's Disease in Chronic Dialysis Patients
por: Yiannopoulou, Konstantina G., et al.
Publicado: (2019) -
Spontaneous, isolated, and gaze‐evoked ocular flutter: A rare case report
por: Vavougios, George D., et al.
Publicado: (2020) -
Current and Future Treatments in Alzheimer Disease: An Update
por: Yiannopoulou, Konstantina G, et al.
Publicado: (2020) -
Early Onset Dementia in Ataxia Associated with Ocular Apraxia Type 1 (AOA1)
por: Aikaterini, Anastasiou I., et al.
Publicado: (2020)